Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer

Journal of Urology

Volumn 191, Issue 3, 2014, Pages 629-637

  Patel, Hiten D ^a   Feng, Zhaoyong ^a   Landis, Patricia ^a   Trock, Bruce J ^a   Epstein, Jonathan I ^a   Carter, H Ballentine ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

biopsy; prostate; prostate specific antigen; prostatic neoplasms; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY;

BIOPSY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT;

EID: 84893855408     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.09.029     Document Type: Article

References (30)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10
2. J. Li, J.A. Djenaba, and A. Soman et al. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007 Prostate Cancer 2012 691380
3. G. Draisma, R. Boer, and S.J. Otto et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868
4. A.S. Glass, M.R. Cooperberg, and M.V. Meng et al. Role of active surveillance in the management of localized prostate cancer J Natl Cancer Inst Monogr 2012 2012 202
5. L. Klotz Active surveillance: the Canadian experience Curr Opin Urol 22 2012 222
6. M.S. Soloway, C.T. Soloway, and S. Williams et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience BJU Int 101 2008 165
7. A.E. Ross, S. Loeb, and P. Landis et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810
8. J.M. Whitson, S.P. Porten, and J.F. Hilton et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer J Urol 185 2011 1656
9. V. Iremashvili, M. Manoharan, and S.D. Lokeshwar et al. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients BJU Int 111 2013 396
10. H.B. Carter, C.H. Morrell, and J.D. Pearson et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease Cancer Res 52 1992 3323
11. H.B. Carter, A. Kettermann, and L. Ferrucci et al. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability Urology 70 2007 685
12. S. Loeb, E.J. Metter, and D. Kan et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer BJU Int 109 2012 508
13. G. Ploussard, E. Xylinas, and L. Salomon et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 56 2009 891
14. R. Abouassaly, B.R. Lane, and J.S. Jones Staging saturation biopsy in patients with prostate cancer on active surveillance protocol Urology 71 2008 573
15. P. Motamedinia, J.L. RiChard, and J.M. McKiernan et al. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance Urology 80 2012 1070
16. D.A. Stackhouse, L. Sun, and F.R. Schroeck et al. Factors predicting prostatic biopsy Gleason sum under grading J Urol 182 2009 118
17. J.J. Tosoian, B.J. Trock, and P. Landis et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185
18. J.I. Epstein, P.C. Walsh, and M. Carmichael et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
19. D. Connolly, A. Black, and L.J. Murray et al. Methods of calculating prostate-specific antigen velocity Eur Urol 52 2007 1044
20. A.E. Kettermann, L. Ferrucci, and B.J. Trock et al. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer BJU Int 106 2010 1284
21. A.J. Stephenson, M.W. Kattan, and J.A. Eastham et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol 27 2009 4300
22. G.L. Andriole, E.D. Crawford, and R.L. Grubb III et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125
23. F.H. Schröder, J. Hugosson, and M.J. Roobol et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981
24. K.L. Greene, P.C. Albertsen, and R.J. Babaian et al. Prostate specific antigen best practice statement: 2009 update J Urol 182 2009 2232
25. D. Ulmert, A.M. Serio, and M.F. O'Brien et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835
26. D.D. Orsted, S.E. Bojesen, and P.R. Kamstrup et al. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality Eur Urol 64 2013 384
27. H.B. Carter, L. Ferrucci, and A. Kettermann et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521
28. S. Loeb, D.E. Sutherland, and A.V. D'Amico et al. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness Urology 72 2008 1116
29. K.S. Tseng, P. Landis, and J.I. Epstein et al. Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779
30. I.F. San Francisco, L. Werner, and M.M. Regan et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance J Urol 185 2011 471